Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer. [electronic resource]
Producer: 20200826Description: e1900631 p. digitalISSN:- 1613-6829
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apolipoprotein E3 -- genetics
- Benzofurans -- administration & dosage
- Drug Administration Schedule
- Drug Carriers -- administration & dosage
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Mice
- Mice, Nude
- Molecular Targeted Therapy -- methods
- Mutation -- drug effects
- NIH 3T3 Cells
- Nanoparticles -- administration & dosage
- Pancreatic Neoplasms -- drug therapy
- Peptide Fragments -- administration & dosage
- Proto-Oncogene Proteins p21(ras) -- antagonists & inhibitors
- RNA, Small Interfering -- administration & dosage
- Signal Transduction -- drug effects
- Transforming Growth Factor beta -- drug effects
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.